Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EDIT vs CADL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CADL Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

CADL Overall Winner 6-Pillar Tally: EDIT 3 – 3 CADL Matrix Metrics: EDIT 3 – 7 CADL

As of Nov 16, 2026, Candel Therapeutics, Inc. (CADL) is the stronger overall head-to-head candidate over Editas Medicine, Inc. (EDIT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EDIT carries a Unified Composite Score of 51.6/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin), whereas CADL carries 46.0/100 (HOLD) at $6.12 (43.5x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. CADL 46.0/100 HOLD), CADL captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY).
  • Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1); meanwhile CADL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EDIT vs CADL
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 35
RSI-14: 35.1 · SMA20: $2.52 · SMA50: $2.61
CADL NASDAQ Head-to-Head Winner
Candel Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.12
-1.21% 1D
Market Cap $642.0M
TTM Revenue $31,000
Forward P/E 43.5x
Beta / 30D Vol 2.14β · 125% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 30
RSI-14: 29.7 · SMA20: $8.32 · SMA50: $9.62

6-Pillar Scorecard Institutional Category Breakdown (EDIT 3 – 3 CADL)

Columns: Metric · EDIT · CADL
1. Valuation Multiples CADL
Forward P/E N/M 43.5x
Trailing P/E N/M 43.5x
PEG Ratio N/M N/M
EV / Revenue 5.2x N/M
2. Growth & Scale EDIT
Revenue Growth (YoY) +37.4% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $50M $31,000
Market Cap $336.5M $642.0M
3. Profitability & Quality CADL
Gross Margin -73.3% N/A
Operating Margin -167.0% 0.0%
Net Profit Margin -144.9% 0.0%
Return on Equity (ROE) -147.4% -93.7%
4. Balance Sheet & Cash Flow CADL
Cash Generation (TTM) -$110M -$57M
Cash Flow Margin N/A N/A
Net Cash / Leverage $79M Net Cash $152M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 95.8% (38th %ile) 85.5% (18th %ile)
Put/Call OI Skew 0.29x (Call-Skewed) 0.50x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EDIT (3) vs CADL (7)
Institutional Metric EDIT CADL Criterion Row Edge
Market Capitalization
Scale
$336.5M $642.0M Larger Scale CADL
Trailing P/E Ratio
Valuation
N/M 43.5x Lower Multiple CADL
Forward P/E Ratio
Valuation
N/M 43.5x Lower Multiple CADL
Revenue Growth (YoY)
Growth
+37.4% +0.0% Higher Growth EDIT
Operating Margin (TTM)
Profitability
-167.0% 0.0% Higher Margin CADL
Net Profit Margin
Profitability
-144.9% 0.0% Higher Margin CADL
Return on Equity (ROE)
Capital Efficiency
-147.4% -93.7% Higher ROE CADL
52-Week Range Position
Momentum
11% ($2–$4) 18% ($4–$14) Stronger Trend CADL
Beta / 30D Volatility
Risk Regime
2.32β · 102% Vol 2.14β · 125% Vol Lower Realized Risk EDIT
Unified Institutional Score
Composite Signal
51.6 / 100 (HOLD) 46.0 / 100 (HOLD) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
$50M $31,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-73.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($79M Net Cash) -$57M ($152M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EDIT +6.27 pp
EDIT: -18.94% · CADL: -25.21%
3M Horizon EDIT +15.32 pp
EDIT: -33.85% · CADL: -49.17%
6M Horizon CADL +2.23 pp
EDIT: -24.7% · CADL: -22.47%
1Y Horizon CADL +57.86 pp
EDIT: -25.0% · CADL: +32.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EDIT Revenue CADL Revenue EDIT Op. Margin CADL Op. Margin Margin Leader
FY2018 $30M N/A -356.1% N/A EDIT
FY2019 $20M N/A -686.4% N/A EDIT
FY2020 $90M $0M -148.6% -11048.0% EDIT
FY2021 $30M $0M -756.1% -20580.8% EDIT
FY2022 $20M $0M -1146.3% -27777.6% EDIT
FY2023 $80M N/A -216.6% N/A EDIT
FY2024 $30M N/A -777.2% N/A EDIT
FY2025 $40M N/A -394.9% N/A EDIT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CADL BREAKDOWN
98d in phase · OBV DISTRIBUTION
Current IV 85.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.50x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CADL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
CADL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $642.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EDIT vs CADL Key Questions & Quantitative Answers

As of Nov 16, 2026, Candel Therapeutics, Inc. (CADL) is the stronger overall head-to-head candidate over Editas Medicine, Inc. (EDIT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EDIT carries a Unified Composite Score of 51.6/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin), whereas CADL carries 46.0/100 (HOLD) at $6.12 (43.5x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. CADL 46.0/100 HOLD), CADL captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY). Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1); meanwhile CADL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EDIT leads the Growth & Scale pillar: EDIT posts +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin), compared with CADL at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $31,000 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EDIT cumulative revenue shifted +33.3% while CADL shifted N/A. In operating R&D and SG&A reinvestment, EDIT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CADL.

CADL screens cheaper on headline valuation multiples. EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin), whereas CADL trades at 43.5x Forward P/E, 43.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EDIT (-147.4% ROE) versus CADL (-93.7% ROE) capital efficiency.

In options market volatility and institutional positioning, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk). By comparison, CADL carries 85.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.14β · 125% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.